Synonyms: CT-327 | CT327 | K-252a-PEG2K | Pegylated K-252 | SNA-120 | SNA120
Compound class:
Synthetic organic
Comment: Pegcantratinib (CT-327/SNA-120) is a clinical stage agent that inhibits the intracellular kinase domain of tropomyosin-related receptor kinase A (TrkA; NTRK1). TrkA is the high affinity receptor for nerve growth factor (NGF), and is a key target in pruritus, within the NGF-TrkA-TRPV1 pathway. As a TrkA inhibitor pegcantratinib is being evaluated as a potential topical treatment for inflammatory skin conditions. Chemically it is a 2kDa PEG derivative of K-252a that was originally developed by Sienna Biopharmaceuticals. PEG conjugation facilitates the delivery of high levels of the active ingredient to skin cells, and avoids the systemic side effects associated with an orally delivered version of the drug.
|
|
Classification | |
Compound class | Synthetic organic |
International Nonproprietary Names | |
INN number | INN |
10009 | pegcantratinib |
Synonyms |
CT-327 | CT327 | K-252a-PEG2K | Pegylated K-252 | SNA-120 | SNA120 |
Database Links | |
CAS Registry No. | 1233363-33-1 (source: WHO INN record) |
GtoPdb PubChem SID | 442878643 |
PubChem CID | 132494168 |
Search Google for chemical match using the InChIKey | MTDVEOMKVDOULD-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | MTDVEOMKVDOULD |
Search PubMed clinical trials | pegcantratinib |
Search PubMed titles | pegcantratinib |
Search PubMed titles/abstracts | pegcantratinib |
UniChem Compound Search for chemical match using the InChIKey | MTDVEOMKVDOULD-UHFFFAOYSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | MTDVEOMKVDOULD-UHFFFAOYSA-N |